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Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual 
practices among men who have sex with men (MSM) are important routes of hepatitis 
C virus (HCV) transmission. Current direct-acting antiviral treatment offers unique 
opportunities for reductions in HCV-related liver disease burden and epidemic control 
in high-risk groups, but these prospects could be counteracted by HCV reinfection 
due to on-going risk behaviours after successful treatment. Based on existing data 
from small and heterogeneous studies of interferon-based treatment, the incidence of 
reinfection after sustained virological response range from 2-6/100 PY among PWID 
to 10-15/100 PY among HIV-infected MSM. These differences mainly reflect 
heterogeneity in study populations with regards to risk behaviours, but also reflect 
variations in study designs and applied virological methods. Increasing levels of 
reinfection are to be expected as we enter the interferon-free treatment era. Individual- 
and population-level efforts to address and prevent reinfection should therefore be 
undertaken when providing HCV care for people with on-going risk behaviour. 
Constructive strategies include acknowledgment without stigma, education and 
counselling, harm reduction optimization, scaled-up treatment including treatment of 






Key points (1) 
- Sharing needle/syringes and contaminated ancillary injecting equipment 
(spoons/cookers, filters, and water) are the main risk factors for HCV 
acquisition among PWID 
- Risk factors for HCV acquisition among MSM include traumatic sexual 
practices, mucosally administered and injecting recreational drug use, HIV 
infection, and ulcerative sexually transmitted infections 
- Combined harm reduction interventions (needle/syringe provision and opioid 
substitution treatment) could reduce HCV transmission among PWID, but 
effective interventions to prevent HCV transmission among MSM have not 
been developed  
- Scaled-up DAA treatment and effective harm reduction/preventive 
interventions are required to substantially reduce HCV prevalence among 
PWID and MSM, but high levels of reinfection due to on-going risk behaviour 
could compromise both individual- and population-level treatment benefits 
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Key points (2) 
- The reported incidence of reinfection after SVR range from 2-6/100 PY in 
studies of PWID to 10-15/100 PY in studies of HIV-infected MSM 
- Differences in reported reinfection estimates reflect heterogeneity in study 
populations with regards to risk behaviour, and variations in study design and 
applied virological methods 
- Higher rates of reinfection might be expected in the DAA treatment era due to 
increased treatment access among people with on-going risk behaviour and 
less concerns for adverse effects of treatment 
- Individual- and population-level strategies to address and prevent reinfection 
include acknowledgement without stigma, education and counselling, harm 
reduction optimization, scaled-up treatment in high-risk groups, treatment of 
injecting networks, post-SVR screening and rapid treatment of reinfections 
- Future studies should assess the incidence of reinfection following DAA 





In high-income countries, injecting risk behaviours among people who inject drugs 
(PWID) and high-risk sexual practices among men who have sex with men (MSM) 
are important routes of hepatitis C virus (HCV) transmission [1-3]. The majority of 
HCV patients in these populations have been chronically infected for many years and 
no longer take part in risk behaviour. Still, approximately one in four individuals with 
chronic HCV acquired through injecting drug use (IDU) have recently injected drugs 
[4] and thereby continue to be at risk of new HCV exposure.  
 
People with on-going risk behaviour have been successfully treated for HCV infection 
[5-7]. However, treatment uptake was low during the interferon era, particularly 
among PWID [8, 9]. With the current availability of tolerable and highly effective 
interferon-free direct-acting antiviral (DAA) drugs, increased treatment rates and 
subsequent rising reinfection rates might be anticipated in high-risk groups. 
 
The potential impact of reinfection is of considerable clinical and public health 
interest [10-12]. High levels of reinfection could compromise individual treatment 
benefits but also impede population efforts to limit the HCV epidemic. This review 
provides updated information on the epidemiology of HCV infection and the risk of 
reinfection after successful treatment in high-risk groups of PWID and MSM. 
Particular emphasis is given to the section on reinfection, in which methodological 
considerations, incidence rates, risk factors, and preventive strategies are discussed.  
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HCV EPIDEMIOLOGY IN HIGH-RISK GROUPS 
HCV epidemiology among PWID 
Prevalence of injecting   
Globally, there are an estimated 14 million PWID (range 11.2-22.0 million) who are 
at risk of HCV infection as a result of injecting practices that may expose them to 
contaminated blood [13]. In most developed countries, IDU increased in the 1970s 
and 1980s and is now the main risk factor for HCV infection in these countries [14-
16]. A recent review estimated the total number of current PWID across Europe to be 
4.5 million [17]. 
 
Prevalence of HCV infection 
Anti-HCV prevalence among PWID has been estimated at 67% worldwide, 
corresponding to 10 million anti-HCV positive PWID (range 6-15.2 million). While 
the prevalence varies greatly between countries, the majority report prevalence 
estimates above 60% [1]. This is the case in Europe, where the recorded midpoint 
prevalence estimates range from 21.1% to 90.5% with approximately half of all 
countries estimated to have 60% prevalence and above [1]. By region, the largest anti-
HCV positive PWID populations are estimated to live in Eastern Europe (2.3 million) 
and East and South-East Asia (2.6 million); by country, the largest PWID populations 
are estimated to live in China (1.6 million), Russian Federation (1.3 million), and the 
USA (1.5 million) [1]. The total number of anti-HCV positive PWID in Europe is 
estimated to be 2.7 million, with 2.0 million being chronically infected [17]. A 
European systematic review estimates the viremic prevalence in PWID to be between 
53% and 97% [18].  
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Incidence of HCV infection 
In contrast to prevalence, no pooled global estimate of incidence among non-
incarcerated PWID has been reported; however, a number of studies have reported 
incidence rates among selected local PWID populations. A systematic review 
(comprising data from nine European countries) identified 11 studies that reported a 
median incidence of 26/100 person-years (PY) among current PWID in the 
community [18]. A review and meta-analysis of HCV in prisons found a summary 
incidence rate of 16.4/100 PY among prisoners with a history of injecting [19]. 
 
Risk factors for HCV acquisition 
Sharing needle/syringes is acknowledged to be the main route of HCV acquisition 
among PWID since direct percutaneous exposure to contaminated blood from a 
needle/syringe has been demonstrated to transmit HCV [20-22]. The risk of 
transmission associated with a given sharing event would, however, depend on a 
number of factors, such as the quantity of blood inoculated and the viral load. 
Ancillary injecting equipment (spoons/cookers, filters, and water) may also become 
contaminated with HCV during the process of preparing and injecting drugs. Sharing 
cookers and filters has been associated with an increased risk of HCV in 
epidemiological studies: while the probability of HCV transmission associated with 
the latter is likely less than that for sharing needles/syringes, the generally higher 
prevalence of sharing cookers/filters may increase their contribution to the proportion 
of new HCV infections [23-25]. While there is evidence of a decline in the rates of 
needle/syringe sharing in some countries, this risk behaviour nevertheless persists 
among PWID [26-28]. A similar decline has been seen in western European countries 
[29-32]; however, the prevalence of sharing needles/syringes may remain high in 
 10 
Eastern Europe [33]. Furthermore, the sharing of ancillary injecting equipment 
appears to remain more prevalent than needle/syringe sharing [29, 34]. 
 
Harm reduction 
Harm reduction is defined as the policies, programmes, and practices that aim to 
reduce the harms associated with the use of psychoactive drugs among people who 
are unable or unwilling to stop [35]. The main harm reduction interventions are 
generally considered to be sterile needle/syringe provision (NSP) and opioid 
substitution treatment (OST). There is evidence to support the effectiveness of NSP 
and OST in reducing injecting risk behaviour, and some evidence to support their 
effectiveness in preventing blood-borne virus transmission among PWID [36, 37].  
 
More recently, studies have demonstrated that the combined impact of NSP and OST 
can produce a greater reduction in HCV transmission than either intervention alone 
[32, 38-40]. These interventions have been endorsed by national, regional, and 
international authorities for the prevention of HCV [41-44]. However, despite the 
availability of, and evidence for, effective harm reduction, most countries have not 
achieved a level of intervention coverage that would likely be required to curb new 
HCV infections: on a global level, there is generally poor coverage of interventions, 
with NSP coverage estimated at 22 sterile needles/syringes per PWID per year and 
OST coverage estimated at 8 OST recipients per 100 PWID. The highest NSP 
coverage is in Australia & New Zealand (202 needles/syringes per PWID per year) 




The experience of some countries that have achieved high levels of harm reduction 
intervention coverage is, however, that they can reduce, but not fully control, HCV 
transmission among PWID [32, 46]. This may be because high coverage needs to be 
sustained for decades in order to have an impact. For example, model projections 
have shown that, in a scenario of 40% viremic prevalence, reducing HCV prevalence 
by a third would require more than 60% coverage of both OST and high coverage 
NSP for 15 years [47]. More impact could probably be achieved through a treatment-
as-prevention strategy: modelling studies have suggested that scaling up HCV therapy 
among active PWID (in addition to the existing harm reduction interventions) is 
necessary if substantial reductions in HCV prevalence over the next decade or two are 
to be made [48, 49].  
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HCV epidemiology among MSM  
Prevalence of HCV infection 
Cross-sectional studies have revealed an anti-HCV prevalence of 1-7% among MSM 
without a history of IDU compared to 25-50% among MSM with a history of IDU 
[50-55]. Further, HCV infection is more frequent among MSM with human 
immunodeficiency virus (HIV) infection (3-39%) than in those without HIV (0-19%) 
[51-53, 56-59]. The HCV prevalence among HIV-negative MSM without IDU is 
comparable to that of the general population [60-63]. 
 
Incidence of HCV infection 
Beginning in 2004, an increase in the incidence of acute HCV infection was reported 
among HIV-infected MSM in Europe, North America, Australia, and Asia [60, 63-80] 
[11, 14-31]. A systematic review of these studies found that the incidence of acute 
HCV from 2000-2012 was approximately four times higher in HIV-positive MSM 
(0.61/100 PY) than HIV-negative MSM (0.15/100 PY) [81]. Data from 3014 HIV-
infected MSM from 12 cohorts within the Concerted Action on SeroConversion to 
AIDS and Death in Europe (CASCADE) collaboration showed that the HCV 
incidence increased from 0.55-0.81/100 PY in 1995 to 2.34-5.11/100 PY in 2007 [76]. 
Similar rises were observed among HIV-infected MSM in North America, Australia, 
and Asia [63, 75, 77, 79, 80]. One phylogenetic analysis revealed a large European-
wide network of HCV transmission among HIV-infected MSM coinciding with the 
introduction of combination antiretroviral therapy and associated increases in sexual 
risk behaviours [82].  
 
Risk factors for HCV acquisition 
 13 
Permucosal (particularly sexual) transmission is the predominant route of HCV 
acquisition among MSM, especially in HIV-infected individuals [53, 83]. Use of 
mucosally administered recreational drugs (e.g. methamphetamines, ketamine, 
gammahydroxybutyrate, lysergic acid diethylamide) [62, 84-87] and high-risk 
traumatic sex practices, particularly unprotected anal intercourse, enema use prior to 
receptive anal intercourse, rectal trauma with bleeding, fisting, and group sex [58, 68, 
72, 84, 85, 87, 88], have been identified as important behavioural risk factors for 
HCV transmission among MSM. The arrival of “chemsex" (i.e. injecting and non- 
injecting drug use to enhance sexual experience) might further promote HCV 
transmission among MSM [89]. Additionally, HIV and ulcerative sexually transmitted 
infections are important biological risk factors for permucosally acquired HCV [68, 
84, 85, 87]. HIV infection increases HCV RNA levels [90] and promotes shedding of 
HCV in serum [91-93]. Ulcerative sexually transmitted infections disrupt the mucosal 
integrity of the genitourinary tract, facilitating HCV permucosal transmission [78, 84, 
85, 87, 88, 94, 95]. 
 
Prevention 
A recent study evaluating a dynamic HCV transmission model among HIV-infected 
MSM in the UK Collaborative HIV Cohort suggested that substantial reductions in 
HCV transmission could be achieved through scale-up of DAA drugs for the 
treatment of chronic HCV and effective behavioural interventions [96]. However, 
effective behavioural interventions to prevent HCV transmission have not been 
developed and tested in MSM. Targeted prevention messages that combine sexual 
health advice and avoidance of recreational drug use and which encourage MSM to 
discuss HCV with their partners might be helpful in preventing HCV infection [97-
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99]. Repeated risk counselling on HCV transmission before, during, and after HCV 
treatment might also be beneficial for HCV prevention [7]. A recent randomized trial 
has shown that a reduction in high-risk sexual practices after a social network 
intervention led to a decline in the incidence of sexually transmitted diseases/HIV 
from 15% to 9% [100]. 
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HCV REINFECTION IN HIGH-RISK GROUPS 
General considerations 
The lack of protective immunity 
HCV reinfection after spontaneous clearance of the virus has been observed in 
chimpanzees [101, 102] and in humans [7, 103-114]. As reviewed elsewhere [115], 
some of these studies have demonstrated evidence of an augmented HCV-specific 
immune response following reinfection compared to after primary infection, 
suggesting that some immunological control may develop after repeated exposure to 
the virus. As this only seems to apply when exposed to a homologous HCV strain, 
one can at best hope for an acquired partial, but no protective, immunity against 
reinfection in clinical practice. The lack of protective immunity has also been evident 
in efforts to develop HCV vaccines, which so far have been complicated by the great 
genetic diversity of HCV, complex immunological responses to the virus, and the 
limited availability of animal models and at-risk cohorts [116, 117].  
 
Heterogeneity and limitations of reinfection studies 
Reinfection following sustained virological response (SVR) has over the last 10-15 
years been documented in several studies in populations of PWID [118-127], 
prisoners [128, 129], and MSM [7, 98, 114, 130-132] (Tables 1 and 2). The 
reinfection incidence estimates reported in these studies have ranged considerably, 
reflecting differences in study populations with regards to risk behaviours, harm 
reduction coverage, and background viremic prevalence. Furthermore, most studies 
have been limited either by small sample sizes, short longitudinal follow-up, 
retrospective study designs, or insufficient risk factor assessment. Finally, differences 
in virological methods may also have biased the reported reinfection estimates and 
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accounted for some of the variation observed between studies. Collectively, all these 
aspects have made generalizability and comparisons between studies challenging.  
 
Testing intervals - “the more often you look” 
Some of the inter-study variability in reinfection estimates could be explained by 
differences in HCV testing intervals [133]. Observational data have demonstrated that 
reinfections often have a transient course with high rates of spontaneous clearance 
[112, 113, 134]. Thus, the event has probably generally been underestimated, as 
reinfection episodes with spontaneous clearance most likely will remain undetected 
unless HCV RNA is tested very frequently. Studies with wide testing intervals will 
therefore mainly capture those reinfections that have become persistent.  
 
Sequencing methods - “the closer you look” 
Recurrence of HCV RNA after SVR could result from one of three possible scenarios: 
late relapse of the pre-treatment majority variant, persistence/re-emergence of a pre-
existing treatment-insensitive minority variant (either detected or undetected), or 
reinfection with a new viral strain not present at baseline [135, 136] (Fig. 1). This is 
an important distinction of both clinical and academic relevance, but correct 
classification is challenging and requires sensitive sequencing methods and robust 
phylogenetic analysis [137]. So far, there has been no standardisation of such 
methods, and studies employing insensitive techniques [7, 119-121, 124, 127-129, 
138] may thus have had a potential to misclassify cases of late relapse as reinfection. 
On the other hand, among individuals with apparent relapse, it is very difficult to 
exclude the possibility of reinfection from the same source as the initial infection. 
 
 17 
The relapse/reinfection distinction rests upon the detection of potential minority 
variants present in pre-treatment samples. This is relevant for individuals with on-
going risk behaviour, who might harbour mixed infections resulting from either co-
infections or superinfections due to repeated exposure to HCV [136]. Conventional 
line probe assays are widely used but have poor sensitivity for detection of minority 
variants that constitute <20% of the total virus population [139-143]. When using 
more sensitive methods [111, 144, 145], the reported prevalence of mixed infection in 
populations of PWID increases from <5% to 20-40%. In a study of MSM with HIV 
co-infection who had failed to respond to interferon-based HCV treatment, 15 of 15 
participants had evidence of mixed infection when next generation sequencing (NGS) 
was performed [146]. Although the presence of mixed infection at baseline may 
compromise interferon-based HCV treatment outcomes [123, 147], its clinical 
significance remains controversial.  
 
Most reinfection studies utilizing sequencing methods have applied majority 
population-based sequencing (i.e. Sanger sequencing) [98, 114, 122, 123, 125, 126], 
but NGS is emerging as the state-of-the-art method [146, 148]. Compared to 
population-based sequencing, NGS offers high throughput analysis with superior 
sensitivity, but at the same time generates large amounts of data that require costly 
bioinformatics and phylogenetic analysis. However, unless the whole genome is 
analysed, the choice of region to be sequenced and the exact design of PCR primers 
may influence the analysis and ultimately lead to misclassification bias [135, 136].  
 
A pragmatic approach 
In studies of low-risk populations, the reported risk of late relapse (i.e. post-SVR 
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recurrence of HCV RNA) is very low, with 5- and 10-year cumulative estimates of 
<1% [149]. In the presence of on-going risk behaviour, post-SVR recurrence of HCV 
RNA therefore most likely represents reinfection. In the absence of a virological gold 
standard to confirm a “true” reinfection diagnosis, we would therefore advise a 
pragmatic approach, taking post-treatment risk factors thoroughly into account.  
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Incidence of HCV reinfection after SVR among PWID  
Reinfection after interferon-based treatment 
Two pioneering studies among former and current PWID [118, 119] confirmed that 
HCV reinfection after SVR was indeed possible, albeit occurring at low rates. Most 
succeeding reports stated similarly low rates, and a meta-analysis [5] of the five first 
studies published from 2002-2012 [118-122] reported a pooled incidence of 2.4/100 
PY. Among individuals with documented on-going risk behaviour after SVR, the 
pooled incidence was moderately higher (6.1/100 PY). However, the results from this 
meta-analysis should be interpreted with caution, as it was based on small studies of 
heterogeneous populations that included patients with relatively short follow-up time. 
Also, these early studies largely lacked sequencing methods to strengthen the 
reinfection diagnosis. 
 
An Australian study among people with acute HCV infection [123], in which 76% 
had a history of IDU and 35% reported recent IDU at enrolment, pioneered sensitive 
sequencing methods using subtype-specific real-time PCRs for detecting mixed HCV 
infection. This study provided a detailed characterization of the natural history of 
reinfection and superinfection (i.e. the detection of a HCV strain distinct from the 
primary strain in those with virological persistence) among treated and untreated 
individuals. Among 67 individuals who achieved SVR, 12 cases of relapse and 5 
cases of reinfection were detected. This generated a higher post-SVR reinfection rate 
(12.3/100 PY) than reported in previous studies, possibly reflecting the inclusion of 
participants with recently acquired HCV infection and still on-going high-risk 
behaviours. This study was also the first to identify independent risk factors for 
reinfection. Reinfection or superinfection occurred significantly more often in 
 20 
participants with poorer baseline social functioning and in those who reported 
methamphetamine injecting compared to opiate injecting during follow-up. 
Interestingly, reinfection was not associated with baseline injecting status, indicating 
that prediction of reinfection may prove difficult in this population. 
 
HCV infection is common in prison populations worldwide [19]. Although the prison 
setting may be considered as an opportunity for HCV treatment, it may also be an 
important site for HCV transmission and hence reinfections. The incidence of 
reinfection after HCV treatment provided in prison was investigated in an 
incarcerated cohort in Spain [129], of which 15% were HIV/HCV co-infected. 
Among 119 prisoners who obtained SVR, 9 (7.6%) were reinfected after a mean 
follow-up of 1.4 years, generating an overall incidence of 5.3/100 PY. Self-reported 
data on risk behaviour were unreliable, as four reinfected individuals reported no risk 
factors; thus, no reasonable reinfection estimate could be given among those who 
continued to inject drugs after treatment. However, reinfection was three times more 
common in HIV-positive than in HIV-negative subjects (13.4 vs. 4.0/100 PY).  
 
Conversely, in another Spanish study of 84 HIV/HCV co-infected individuals [125], a 
much lower incidence of reinfection (1.2/100 PY) was found. This was an overall 
low-risk population mainly comprising former PWID or individuals on stable OST, 
but in the subgroup reporting risk behaviours during follow-up, 3 of 11 were 
reinfected (incidence 8.7/100PY). 
 
A newly published comprehensive meta-analysis [150] included 14 articles or 
conference abstracts among PWID or prisoners and 4 studies of HIV/HCV co-
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infected individuals from heterogeneous populations. Among a total of 771 PWID or 
prisoners, 42 cases of HCV RNA recurrence after SVR were observed. The pooled 
reinfection incidence was 1.9/100 PY, leading to an estimated 5-year risk of 10%. 
Among HIV/HCV co-infected individuals, the pooled incidence of reinfection was 
higher (3.2/100 PY), leading to an estimated 5-year risk of 15%. However, given that 
these estimates largely were based on data from small studies, there is still 
considerable uncertainty regarding generalizability and the actual long-term risk of 
reinfection. 
 
In a recent Norwegian study [126], long-term reinfection rates were assessed in 94 
individuals with a history of IDU who had achieved SVR in a treatment trial 
performed in 2002-2004. Notably, the study population was not a typical high-risk 
group, as six months of abstinence from IDU was required before treatment. 
Nevertheless, 39% had relapsed to IDU at some point after treatment. After a median 
of seven years after SVR, persistent reinfection was observed in 11% of individuals 
with a history of IDU prior to treatment (incidence 1.7/100 PY) and in 27% of 
individuals who reported IDU after treatment (incidence 4.9/100 PY). Although all 
episodes occurred among individuals with IDU after treatment, reinfection was not 
associated with any baseline variable; however, relapse to IDU was associated with 
younger age and low education level. While these estimates are in line with previous 
reports, direct comparison may be difficult due to the study’s retrospective design 
with wide testing intervals and subsequent underestimation of all reinfection episodes. 
The study also highlights the vulnerability of viral sequencing of old serum samples 
with degradation of HCV RNA and low viral loads, which led to adequate sequences 
being obtained only in a minority of samples. 
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The long-term risk of reinfection has also been evaluated retrospectively in a large 
Scottish cohort of former and current PWID who had obtained SVR between 2000-
2009 [127]. Risk behaviour post-SVR was assessed by registry linkage, and 
hospitalisation for an opiate- or injection-related cause during follow-up was 
considered a proxy for continued IDU. Among 277 individuals who were tested for 
HCV RNA after SVR, 7 reinfections were observed after a median of 4.5 years. 
Consistent with results from previous studies, the reinfection incidence was 1.7/100 
PY among all included individuals and 5.7/100 PY among the proportion (11%) with 
continued IDU documented during follow-up.  
 
Reinfection after DAA treatment 
As HCV treatment for PWID becomes more feasible with interferon-free therapy, 
reinfection may become a more common event. The adverse events of interferon-
based treatment have required close interaction with health care providers, offering 
opportunities for interventions aimed at achieving beneficial behavioural change [37, 
151]. For some, interferon itself might even have provided a “cathartic” effect, 
resulting in efforts to protect one’s SVR. One might therefore speculate that the 
potential for behavioural change will decrease in the emerging interferon-free era.  
 
So far, no published studies have evaluated the risk of reinfection following DAA 
treatment, but some data has been presented as abstracts. Of 3004 patients who 
achieved SVR12 in the Phase 3 studies of sofosbuvir [152], which notably excluded 
patients with recent illicit drug use or OST, 12 cases of recurrence of HCV RNA were 
identified after 3 months of follow-up. Based on results from deep sequencing of the 
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NS5B segment, 7 of 12 cases represented reinfection while 5 of 12 cases represented 
late relapse. These findings suggest that among cases with HCV recurrence post-
SVR12, most can be attributed to reinfection even in presumed low-risk populations. 
 
Reinfection was also assessed in a recent study of elbasvir/grazoprevir in HCV 
patients receiving opioid agonist therapy [153]. Given that one-half of included 
individuals had detectable illicit drugs (excluding marijuana) in urine throughout the 
study, this population could be considered at high risk of reinfection. SVR12 was 
achieved in 184 of 201 (91%) patients and virological failure could be attributed to 
relapse in 7 patients and reinfection in 5 patients. The reinfection diagnosis was based 
on population-based sequencing of the NS3 and NS5A segments, supported by 
positive urinary drug screening in 4 of 5 individuals. Two of the cases with 
reinfection were subsequently HCV RNA negative, confirming that an important 
proportion of reinfections might clear spontaneously also after DAA treatment.   
 24 
Incidence of HCV reinfection after SVR among MSM 
Data on HCV reinfection among MSM are mainly limited to HIV-infected 
individuals. In addition, most studies have focused on reinfection following treatment 
of acute HCV infection [7, 98, 114, 130, 131], and few data are available on the 
incidence of reinfection after treatment of chronic HCV infection [7, 125]. However, 
in a British study [7] among HIV/HCV co-infected MSM that included both acute 
infections and cases of unknown duration, data on reinfection was reported for 46 
individuals with unknown date of HCV infection. Among those, 12 (26%) were 
reinfected after spontaneous or treatment-induced clearance. The overall reinfection 
rate was 7.8/100 PY, slightly lower than among individuals with acute HCV infection. 
 
High rates of reinfection in HIV-positive MSM following successful treatment of 
acute HCV infection have been reported in several studies [7, 98, 114, 130, 131]. In a 
study from Amsterdam [98], 11 of 51 individuals who achieved SVR were reinfected 
after a median follow-up of 1.3 years. The incidence of reinfection was 15.2/100 PY 
and the cumulative incidence was 33% within 2 years. The reinfection diagnosis was 
supported by sequencing of the E2-HVR1 region, and behavioural data, available in 
21 MSM, showed that non-injecting drug use was more frequent in reinfected 
individuals. In a study from London [7], 27 reinfections occurred among 114 
individuals with SVR after treatment of acute infection, yielding a reinfection rate of 
9.6/100 PY and a 2-year cumulative rate of 25%. In addition, there were six second 
reinfections occurring after successful treatment of the 13 first reinfections. No 
behavioural data was reported in this study. The pooled reinfection rate for these two 
studies was 11.4/100 PY [131]. 
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Two other studies estimated the frequency of reinfection after either spontaneous 
clearance or SVR during unreported periods of observation [114, 130]. In a Dutch 
study [130], 12 of 31 (39%) HIV-infected MSM who obtained SVR after treatment of 
acute HCV infection were reinfected. In addition, four MSM were reinfected during 
treatment, before reaching SVR. Another study assessed reinfection after SVR in four 
sites in Germany from 2001 to 2013 [114]. Among 302 MSM with either spontaneous 
or treatment-induced clearance of acute HCV infection, 48 first reinfections (16%) 
were detected. Of those, 42 achieved SVR, one was reinfected again before reaching 
SVR and five spontaneously cleared their reinfection. After a median time of 13 
months after HCV clearance, there were 11 second reinfections (personal 
communication, P. Ingiliz). All episodes occurred in MSM who did not report 
injecting drug use.  
 
In a recent European multi-centre collaboration [132], the rates of reinfection were 
estimated among 606 HIV-positive MSM with confirmed SVR or spontaneous 
clearance. Over 3 years of follow-up, 149 patients (25%) were reinfected, with an 
overall incidence rate of 7.6/100 PY. A second, third and fourth reinfection were 
detected in 69, 13 and 2 individuals respectively, and the incidence of second 
reinfection was 19.9/100 PY. The incidence varied between cities, with highest rates 
observed in Paris (21.8/100 PY). Behavioural data was not reported in this study. 
 
Risk behaviours have not been systematically assessed in these studies, and factors 
associated with reinfection have therefore not been clarified among MSM. It is, 
however, conceivable that they are similar to those reported for primary HCV 
infection. In particular, the introduction of “chemsex” has likely facilitated HCV 
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Comparison of reinfection rates among PWID and MSM 
Based on existing data from small and heterogeneous studies of interferon-based 
treatment to former and current PWID, the incidence of HCV reinfection following 
SVR is approximately 2/100 PY in people with a history of IDU, increasing to around 
6/100 PY in people with on-going IDU. The cumulative overall risk of reinfection 
calculated from all studies of PWID or prisoners reporting data on PY is 2.1/100 PY 
(43 reinfections over 2082 PY; Table 2). This is a significant risk, but still lower than 
rates of primary HCV infection reported in PWID outside the treatment setting [115].  
 
Data on reinfection after SVR among MSM are also limited, but the reported 
incidence rates are considerably higher (10-15/100 PY) among HIV-infected MSM 
than among PWID, and may even exceed rates of primary HCV infection. The 
cumulative risk of reinfection calculated from studies of MSM reporting data on PY is 
12.8/100 PY (38 reinfections over 296 PY; Table 2). These results, however, may not 
be generalizable to HIV-uninfected MSM. Moreover, epidemic outbreaks have been 
reported only in certain large cities, whereas acute HCV and reinfections continue to 
be uncommon among MSM in many areas with high prevalence of HIV/HCV co-
infection [154]. 
 
There are some considerations to be made when interpreting the differences in 
reinfection rates between PWID and MSM. First, most studies among PWID were 
carried out in selected populations with chronic HCV infection, often including 
individuals without on-going risk behaviour at the time of treatment. Conversely, 
studies of MSM mainly included individuals with acute HCV infection who probably 
continued to be engaged in risk behaviours during and after treatment. Second, MSM 
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often have multiple risk factors for reinfection, including drug use as a sexual 
enhancer. Furthermore, HIV infection is a biological risk factor for HCV transmission 
more prevalent among MSM than among PWID. Table 3 summarizes important 
epidemiological differences between PWID and MSM.  
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Addressing reinfection 
High cumulative rates of reinfection are to be expected as we enter the interferon-free 
treatment era. This could negate individual long-term treatment benefits and challenge 
the potential to prevent HCV-related liver disease morbidity and mortality in high-risk 
populations. High rates of reinfection would also allow continued HCV transmission 
and might compromise population-level treatment as prevention benefits [12]. 
  
Efforts to address and prevent reinfection should therefore be undertaken when 
providing HCV care for people with on-going risk behaviour. Acknowledgement of 
the problem without stigma and discrimination is the crucial first step; reinfections 
will occur and simply confirms that the target population is being treated. However, 
individual-level prevention of reinfection faces the same challenges as prevention of 
primary infection, and there are no data evaluating the impact of such interventions on 
reinfection. Nevertheless, all patients should be offered information, education and 
counselling about the risk of reinfection associated with high-risk sexual practices and 
unsafe drug use [37, 155]. Repeated safe sex counselling from health care providers 
and peers may be considered for HIV-infected MSM with high-risk behaviour [7, 97-
100]. Combined harm reduction interventions should be optimized for all active 
injectors and HCV care should preferably be integrated in multidisciplinary settings 
[37, 156, 157]. The potential role of a prophylactic HCV vaccine for high-risk groups 
remains to be seen, but results from an on-going vaccine trial among PWID are highly 
anticipated [117, 158]. 
 
At the population-level, HCV treatment for high-risk groups could represent an 
opportunity for epidemic control [49, 159]. Individuals at high risk of reinfection are 
 30 
probably also the ones most likely to transmit the virus forward. Targeted antiviral 
treatment for high-risk transmitters may therefore have great prevention potential, as 
these individuals, even if only temporarily, are kept out of the viremic pool. Despite 
the lack of empirical data, this perspective is supported by current international 
treatment guidelines that recommend prioritized treatment for PWID and MSM 
regardless of fibrosis stage [160-162].  
 
As HCV incidence will depend on the viremic prevalence in a given population, rapid 
treatment scale-up in high-risk populations could be necessary to reduce the impact of 
reinfection over time [163]. Conversely, a slow scale-up could create an increasing 
number of susceptible individuals without reduction of the viremic reservoir. 
Consequently, early detection and retreatment of reinfections may be required to 
counteract the negative effects of reinfection at both individual and population levels. 
Individuals with a high probability of continued high-risk behaviour after SVR should 
therefore undergo annual HCV RNA screening within a multidisciplinary treatment 
setting and quickly get access to retreatment if reinfection is detected.   
 
PWID rarely contribute to international HCV transmission, but instead engage in 
small local networks of injection partners [164, 165]. Injecting networks powerfully 
influence the transmission of HCV and could inform treatment-as-prevention 
strategies among PWID. In clinical practice, however, most often single persons 
within such networks are treated, resulting in a high reinfection risk. A feasible 
approach, both in settings of primary infection and reinfection, could therefore be to 
explore and treat whole networks using a “bring your friends”-strategy [166].  
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More data on reinfection are needed in a field rapidly moving forward. The incidence 
of reinfection following DAA treatment is unknown and should be assessed carefully 
in prospective clinical trials. Importantly, future research should evaluate the 
feasibility of potential prevention and retreatment strategies within controlled studies.   
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CONCLUSION 
Current DAA treatment offers unique opportunities for reductions in HCV-related 
liver disease burden and epidemic control in high-risk populations of PWID and 
MSM. However, increasing rates of reinfection after successful treatment due to on-
going risk behaviours should be anticipated and acknowledged without stigma. 
Constructive preventive strategies include education and counselling, harm reduction 
optimization, scaled-up treatment in high-risk groups including treatment of injecting 
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TABLES AND FIGURE LEGENDS 
 
Table 1. Characteristics of studies of hepatitis C virus reinfection after sustained 




PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained 
virological response; HCV, hepatitis C virus; HIV, human immunodeficiency virus; 
OST, opioid substitution treatment; NR, not reported; NA, not applicable  
Study Location Design SVR Population HCV 
infection 










27 PWID Chronic 0% 0% 0% 33% 




18 PWID Chronic NR 39% NR 50% 






9 PWID Chronic 56% NR 0% 22% 




35 PWID Chronic 6% 43% 54% 46% 




42 PWID Chronic 2% 93% 100% 26% 




67 PWID Acute 33% NR 35% 38% 




23 PWID Chronic 0% 27% 85% NR 




84 PWID Chronic 100% 24% NR 15% 




94 PWID Chronic 0% 0% 0% 39% 




277 PWID Chronic NR NR NR 11% 




53 Prisoners Chronic 0% NR NR NR 




119 Prisoners Chronic 15% 100% 20% NR 




51 MSM Acute 100% NA NR NR 




Retrospective 114 MSM Acute 
/unknown 
100% NA NR NR 
Vanhommerig 
et al 2014 [130] 
Netherlands Retrospective 31 MSM Acute 100% NA NR NR 
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Table 2. Incidence estimates of hepatitis C reinfection after sustained virological 
response and applied methods in studies among people who inject drugs and men who 
have sex with men 
 
*
 Persistent reinfections 
PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained 
virological response; FU, follow-up; PYFU, person-years of follow-up; PY, person-
years; NR, not reported 
  














per 100 PY 
Dalgard et al 
2002 [118] 
PWID 27 5.4 118/40 Genotyping 
Risk factors 
1-7 1 0.8/2.5 
Backmund et al 
2004 [119] 
PWID 18 2.8 51/24 Genotyping 
Risk factors 
1 2 3.9/8.4 
Currie et al 
2008 [120] 
PWID 9 3.6 38/3.5 HCV RNA 
Risk factors 
0.5 1 0.56/1.89 
Grebely et al 
2010 [121] 
PWID 35 2.0 63/38 Genotyping 
Risk factors 
1 2 3.2/5.3 
Grady et al 
2012 [122] 
PWID 42 2.5 132/32 Sequencing 0.5-1 1 0.8/3.4 
Grebely et al 
2012 [123] 
PWID 67 1.1 140/56 Sequencing  
Risk factors 
0-2 5 12.3/7.3 
Hilsden et al 
2013 [124] 
PWID 23 1.8 36/NR HCV RNA NR 1 2.8/NR 
Pineda et al 
2015 [125] 
PWID 84 2.8 330/NR Sequencing 
Risk factors 
0.5 4 1.2/8.7 
Midgard et al 
2016 [126] 
PWID 94 7.1 593/206 Sequencing  
Risk factors 
0.5-8 10* 1.7/4.9 
Weir et al 2016 
[127]  
PWID 277 4.5 410/NR Genotyping 
Risk factors 
NR 7 1.7/5.7 
Bate et al 2010 
[128] 
Prisoners 53 3.4 NR Genotyping NR 5 NR 
Marco et al 
2013 [129] 
Prisoners 119 1.4 171/NR Genotyping 
Risk factors 
1 9 5.3/NR 
Lambers et al 
2011 [98] 
MSM 55 1.3 72/NR Sequencing 
Risk factors 
0.25 11 15.2/NR 
Martin et al 
2013 [7] 
MSM 114 1.6 224/NR HCV RNA NR 27 9.6/NR 
Vanhommerig 
et al 2014 [130] 
MSM 31 4.0 NR Sequencing 0.5 8 NR 
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Table 3. Differences in hepatitis C epidemiology among people who inject drugs and 
men who have sex with men 
 
 PWID MSM 
HCV prevalence High Low* 
Proportion of total HCV population  Large Small 
Access to HCV care Poor Good 
Treatment of acute HCV infection Rare Common 
Risk behaviours post-SVR Variable Prevalent 
Transmission networks Local International 
Reinfection rates 2-6/100 PY 10-15/100 PY 
*Mainly limited to HIV-infected 
PWID, people who inject drugs; MSM, men who have sex with men; SVR, sustained 
virological response; PY, person-years 
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Fig. 1. Recurrence of HCV RNA after sustained virological response could result 
from either (A) late relapse of a majority variant, (B) persistence/re-emergence of a 
pre-existing minority variant, or (C) reinfection with a new viral strain. 
 
TW0, treatment week 0; EOT, end of treatment; SVR, sustained virological response; 
LOD, level of detection. 
